On the other hand, higher serum IL-13 levels and the presence of PD-L2 rs7854413, C allele carriers states are directly associated with advanced fibrosis progression in NASH patients (OR = 1.432 95%, CI = 1.022–2.008, p = 0.037) and (OR = 3.797, 95% CI = 1.216–11.875, p = 0.022), respectively, as shown in Table 5. Here, IL13 is linked to metabolic dysfunction-associated steatohepatitis.